DermatologistsBlog.com: What are the main findings of the study?
Dr. Markus: This was a head to head double-blind study against Humira® (adalimumab) that evaluated safety and efficacy of ABP 501 compared to adalimumab in adult patients with moderate to severe plaque psoriasis. The primary endpoint was the Psoriasis Area and Severity Index (PASI) percent improvement from baseline to week 16 of treatment and we are pleased to announce that we met our primary endpoint. The PASI percent improvement from baseline to week 16 was within the predefined equivalence margin. Additionally, the safety and immunogenicity were comparable for ABP 501 and adalimumab.